|
|
|
|
|
|
|
|
|
|
partial view
In this issue of Annals of Oncology,
Fujiwara and co-workers present the detailed results of health-related
quality of life (QoL) of the randomized, placebo-controlled
trial testing the addition of the
anti-angiopoietin agent trebananib to weekly paclitaxel in patients with
recurrent epithelial
ovarian cancer. As detailed in the primary
publication, trebananib produced a 1.6-month improvement in median
progression-free
survival (PFS): experimental treatment was
globally well tolerated, although associated with a high incidence of
oedema [1]. In this second paper, the authors show that side-effects had not a relevant QoL impact, concluding that the PFS improvement
was obtained without compromising patients' QoL.
As a general rule, patient-reported outcomes and QoL results may have a great relevance in the global interpretation of the
results of a clinical trial.
Even when the experimental treatment
demonstrates a clinically relevant efficacy (for instance, an overall
survival gain or
a great prolongation of PFS), patient-reported
outcomes and QoL results are still important to allow a complete picture
of
benefits and harms associated with treatment. By
knowing details of treatment impact on QoL, clinicians and future
patients
in clinical practice will have a balanced
description of both sides of the coin, i.e. the auspicated effect on
symptoms caused
by the disease (that will be …
...women with recurrent ovarian cancer receiving paclitaxel...TRINOVA-1) K. Fujiwara 1 * B. J. Monk 2 C...Correspondence to: Dr Keiichi Fujiwara, Department of Gynecologic...81-42-984-4741; E-mail: fujiwara@saitama-med.ac...women with recurrent ovarian cancer demonstrate that...
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.